Articles

The Asia Pacific region is fast becoming the growth center of the worldwide pharmaceuticals market. By 2015, these markets are projected to account for almost a third of the total pharmaceutical sales worldwide. But with this increased demand comes an intensified focus on pharmacovigilance and drug safety. Pharma IQ takes a look at 5 challenges that continue to plague the pharmacovigilance sector. Read more

How many times have you heard in your organisation:‘oh you can’t do that here, it’s impossible.’ Perhaps it’s something you’ve quietly thought yourself. While change is very often a great thing, bringing more good than bad to an organisation, many of us look at it as a time-consuming upheaval to our daily working lives and prefer to recoil into the comfortable space of the familiar. Pharma IQ has put the feelers out into the Biotech community and come up with some Top Tips which will help make what appears impossible in your organisation, possible Read more

The Congressional Budget Office (CBO) has estimated that the United States could save $25 billion from the use of biosimilars over 10 years. In a general sense the term biosimilars refers to follow on biologics or follow on proteins that meet and or satisfy the very high standards often associated with comparability, i.e. safety, efficacy, purity, and potency already established by the approved originator biologic product. Read more

Fergus Sweeney, Head of Compliance and Inspection, Patient Health Protection at European Medicines Agency (EMA), joins Pharma IQ to discuss coordinating worldwide inspection procedures, working closer with the FDA and the development of the Clinical Trial Register. Read more

Social media and the internet are increasingly been used as a means to sell illegal and counterfeit drugs, a UN drugs agency has warned. This comes in the wake of a recent industry alarm when fake batches of the cancer drug Avastin came onto the US market increasing fears about drug safety. A recent report by MarkMonitor estimated that online counterfeit sales cost businesses $135 billion (£87 billion) in revenue in 2011. Read more

Cases of counterfeit pharmaceuticals being discovered entering the United States are on the up. Up 200 percent to $11 million (£7 million) in 2011 to be precise, based on the domestic value of seizures from the Customs and Border Protection (CBP) last year. Read more

Due to the important role that such files can play in the dealings of businesses, it is unsurprising that the past few months have thrown up some debate around e-discovery, particularly its relationship with social media. Read more

With the success such companies are already seeing in other markets, they can also afford to wait. In its results for the first fiscal quarter of 2012, Dr Reddy's revealed a 69 percent year-on-year increase in revenues from its biosimilars portfolio in India, with the segment now representing 7 percent of overall sales. Read more

This year has already seen the number of new drugs approved by the United States Food and Drug Administration (FDA) match the total number approved in 2010. Read more

The collection of drug safety information is one area in which major players in the industry believe social media could prove a valuable tool and research suggests consumers are likely to oblige. Read more